 | |||||||
| technology | |||||||
| NEWS | |||||||
BOND-003 Cohort C Trial Results for Cretostimogene Grenadenorepvec in BCG-Unresponsive Bladder Cancer - Mark ... Dr. Tyson explains this single-arm phase 3 study enrolled patients with BCG-unresponsive CIS who received six induction doses of cretostimogene followed by maintenance doses. The trial demonstrated a complete response rate of 75.5%, with 46% disease-free ...
| |||||||
| See more results | Edit this alert | |||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment